Home › Funds › Soleus Capital Management, L.P. › INBX

Soleus Capital Management, L.P. position in INBX

INHIBRX BIOSCIENCES INC · Health Care

Soleus Capital Management, L.P. reported holding 210,000 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$21.0M, representing 0.75% of its reported portfolio and ranking #31 among its reported holdings. Soleus Capital Management, L.P. has disclosed INBX holdings in 7 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)210.00K sh
Reported value held$21.02M
Portfolio Weight0.75%
First reportedQ3 2023
Last changeNew
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s INBX position evolved

Soleus Capital Management, L.P. first disclosed a stake in INBX in Q3 2023 at 549,183 shares (US$10.1M). The position peaked in Q3 2026 at 210,000 shares, worth US$21.0M. Across 7 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 210,000 shares valued at US$21.0M. Notable position changes include a 97% trim in Q4 2023, a 1686% increase in Q1 2024, a 424% increase in Q1 2026 (shares rose 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 549.18K $10.08M New
Q4 2023 15.00K $570.00K Reduce
Q1 2024 267.87K $9.36M Add
Q2 2024 88.47K $1.25M Reduce
Q4 2025 25.00K $1.98M New
Q1 2026 131.00K $8.81M Add
Q3 2026 210.00K $21.02M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About INBX and 13F data

INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 40 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$129.3M), Sanofi (US$115.9M), Schonfeld Strategic Advisors LLC (US$82.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding INBX

All INBX fund holders →

FAQ

How long has Soleus Capital Management, L.P. held INBX?

Soleus Capital Management, L.P. has disclosed INBX holdings in 7 of the last 13 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in INBX?

As of Q3 2026, Soleus Capital Management, L.P. holds 210.00K shares of INBX (INHIBRX BIOSCIENCES INC), valued at $21.02M, representing 0.75% of its reported portfolio and ranking #31.

Has Soleus Capital Management, L.P. been buying or selling INBX?

In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. newly opened its position in INBX. The position peaked in Q3 2026 at 210.00K shares.

Which other funds hold INBX?

Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, Schonfeld Strategic Advisors LLC, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.